Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era

BACKGROUND: Monoclonal antibody (mAb) treatment is associated with decreased risk of hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 (COVID-19) caused by early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Bebtelovimab exhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreary, Erin K, Kip, Kevin E, Collins, Kevin, Minnier, Tami E, Snyder, Graham M, Steiner, Ashley, Meyers, Russell, Borneman, Tina, Adam, Michelle, Thurau, Lauren, Yealy, Donald M, Huang, David T, Bariola, J Ryan, Schmidhofer, Mark, Wadas, Richard J, Angus, Derek C, Kip, Paula L, Marroquin, Oscar C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619560/
https://www.ncbi.nlm.nih.gov/pubmed/36324319
http://dx.doi.org/10.1093/ofid/ofac517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619560/
https://www.ncbi.nlm.nih.gov/pubmed/36324319
http://dx.doi.org/10.1093/ofid/ofac517

Ejemplares similares